ReviewDiagnostics (Basel, Switzerland)2026
Restoring the Airway Barrier: How Targeting Eosinophilic Inflammation Shapes Epithelial Health and Clinical Remission in Asthma.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogeneous chronic airway disease in which eosinophilic inflammation represents a major type 2 endotype. The airway epithelium plays a central role in disease pathobiology by regulating barrier integrity, immune signaling, and tissue repair. In eosinophilic asthma, interactions between eosinophils and epithelial cells are associated with epithelial barrier disruption, altered differentiation, mucus hypersecretion, and airway remodeling. This review summarizes current evidence on the role of eosinophils in epithelial dysfunction and discusses biomarkers of epithelial injury, including epithelial-derived alarmins, chemokines, secretory proteins, and structural junctional markers. These biomarkers reflect different aspects of epithelial activation, injury, and repair and may contribute to improved characterization of disease mechanisms and inflammatory endotypes. The effects of biologic therapies targeting eosinophilic inflammation are also reviewed. While these treatments are associated with improved clinical outcomes and reduced eosinophil levels, available evidence indicates that epithelial alterations and remodeling processes may persist despite treatment. Overall, integrating epithelial biomarkers with clinical and inflammatory parameters may provide additional insight into disease activity and support more comprehensive assessment of asthma beyond conventional measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.